Idiopathic Parkinson's disease patient‐derived induced pluripotent stem cells function as midbrain dopaminergic neurons in rodent brains. Issue 9 (24th February 2017)

• Record Type: Journal Article
• Authors: Kikuchi, Tetsuhiro; Morizane, Asuka; Doi, Daisuke; Okita, Keisuke; Nakagawa, Masato; Yamakado, Hodaka; Inoue, Haruhisa; Takahashi, Ryosuke; Takahashi, Jun
• Is Part Of: Journal of neuroscience research. Volume 95:Issue 9(2017)
• Page Start: 1829
• Page End: 1837
• Publication Date: 2017-02-24
• Subjects: Parkinson's disease -- transplantation -- transgenic mice -- rat brain -- dopaminergic neurons; Neurobiology -- Periodicals; 612
• DOI: 10.1002/jnr.24014
• Languages: English
• ISSNs: 0360-4012

Abstract

Abstract : Patient‐specific induced pluripotent stem cells (iPSCs) are a promising source for cell transplantation therapy. In Parkinson's disease (PD) patients, however, their vulnerability and the transmission of pathological α‐Synuclein are possible drawbacks that may prevent PD‐specific iPSCs (PDiPSCs) from being used in clinical settings. In this study, we generated iPSCs from idiopathic PD patients and found that there was no significant vulnerability between dopaminergic (DA) neurons generated from healthy individuals and idiopathic PD patients. PDiPSC‐derived DA neurons survived and functioned in the brains of PD model rats. In addition, in the brains of α‐Synuclein transgenic mice, PDiPSC‐derived DA neurons did not cause pathological α‐Synuclein accumulation in the host brain or in the grafts. These results suggested that iPSCs derived from idiopathic PD patients are feasible as donor cells for autologous transplantation to treat PD. © 2017 Wiley Periodicals, Inc. Abstract : Dopaminergic neurons generated from induced pluripotent stem cells of Parkinson's disease patient caused behavioral improvement of 6‐OHDA‐lesioned rats as well as those derived from healthy individual. Even in the brains of α‐Synuclein transgenic mice, there was no sign of the transfer of pathological α‐Synuclein, suggesting their applicability for autologous transplantation.